An approved drug for migraines can help triple breast cancer treatment, the most deadly form of breast cancer of women, according to an international study.
The study was conducted by researchers at the University of Paillo Medical College and the National Taiwan University School of Medicine and published the results of the study in the latest edition of Scientific Reports, the Anatolia news agency reported.
The team conducted its study to monitor the effectiveness of Flunarizine, approved by the US Food and Drug Administration (FDA) to prevent migraines. The study is part of a series of scientific research on approved drugs in a strategy to reduce the cost of developing new drugs, speeding up production and ensuring safety.
The researchers focused on finding drug compounds targeting a layer of protein called N-Ras, which are powerful engines for a wide range of cancers, most notably breast cancer. In a study of mice with negative triple breast cancer, the team discovered that flonarizine had the potential to slow the growth of cancer cells.
The study showed that the drug targets N-Ras protein pathways and thus reduces its volume in cancer cells by altering the normal cell’s ability to break down the protein.
“Fluarazine has been used for decades to treat dizziness, dizziness and migraine prevention,” said co-author Dr Eric Sechang. “Our study showed a new function of the drug by targeting the N-Ras protein, which plays a key role in the spread of breast cancer cells,” he said.
He pointed out that the results of the study are evidence that this approach can lead to the discovery of drugs faster and less expensive than the traditional methods of drug development.
According to the World Health Organization’s International Agency for Research on Cancer, breast cancer is the most common type of tumor among women worldwide, and in the Middle East in particular. About 1.4 million new cases are diagnosed every year, killing more than 450,000 Ladies annually around the world.